Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients

Compugen advances COM701 in ovarian cancer with strong partners, key catalysts ahead, and funding into 2027. Find out why CGEN stock is a buy.